Vinva Investment Management Ltd Purchases 16,704 Shares of Cencora, Inc. (NYSE:COR)

Vinva Investment Management Ltd grew its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 204.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 24,886 shares of the company's stock after acquiring an additional 16,704 shares during the period. Vinva Investment Management Ltd's holdings in Cencora were worth $5,592,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. State Street Corp raised its stake in Cencora by 3.8% in the 3rd quarter. State Street Corp now owns 8,045,896 shares of the company's stock valued at $1,810,970,000 after acquiring an additional 291,867 shares during the period. Wellington Management Group LLP raised its position in shares of Cencora by 7.0% in the third quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after purchasing an additional 338,452 shares during the period. Boston Partners lifted its stake in shares of Cencora by 2.6% during the 4th quarter. Boston Partners now owns 5,007,100 shares of the company's stock valued at $1,128,058,000 after buying an additional 125,611 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Cencora by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,195,851 shares of the company's stock valued at $941,183,000 after buying an additional 189,054 shares in the last quarter. Finally, Pacer Advisors Inc. grew its stake in Cencora by 6.7% in the 4th quarter. Pacer Advisors Inc. now owns 2,204,242 shares of the company's stock valued at $495,249,000 after buying an additional 138,868 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research firms have issued reports on COR. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price on the stock. JPMorgan Chase & Co. raised their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Evercore ISI upped their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Wells Fargo & Company raised their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Finally, StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $280.20.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,970 shares of company stock worth $2,998,670. 10.80% of the stock is currently owned by insiders.

Cencora Price Performance

Shares of Cencora stock traded down $0.13 on Monday, hitting $267.30. 1,056,808 shares of the company traded hands, compared to its average volume of 1,377,904. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $277.61. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The company has a market cap of $51.83 billion, a P/E ratio of 38.02, a P/E/G ratio of 1.31 and a beta of 0.51. The firm's 50-day simple moving average is $250.62 and its 200 day simple moving average is $240.01.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.82%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio (DPR) is presently 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.